Jagadeesha's brain, the first juvenile Huntington's Disease donation in India, offers hope for vital neurodegenerative research at NIMHANS.

UniQure stock crashed Monday on "confusing" and "unexpected" feedback from the FDA for its Huntington's disease gene therapy.

The firm, which had planned to submit a BLA in 2026 for AMT-130, described the FDA's latest feedback as a "drastic change" and "unexpected." ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...

In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now ...

UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment Shares of UniQure sank in premarket trading after the company said it received negative feedback from the Food and ...

LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

On November 3, 2025, uniQure announced a regulatory update regarding its investigational gene therapy for Huntington’s disease, AMT-130 ... advancing transformative therapies for patients with severe ...

Qure's stock narrative has been recently revised, with the Fair Value Estimate remaining constant at $75.09 per share while the discount rate ticked up marginally from 6.70% to 6.76%. This comes amid ...

Pivotal results from uniQure’s gene therapy for Huntington’s disease have brought new light to patients who have known only ...

Sex influences how genetic and age-related factors translate into clinical and neuroimaging trajectories in Huntington disease.

SOM Biotech, a clinical-stage company dedicated to the discovery and development of innovative therapies for rare central nervous system disorders, announces today that it has received the final ...